Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects

Molecular Metabolism

Volumn 6, Issue 2, 2017, Pages 226-231

  Yanagimachi, Tsuyoshi ^a   Fujita, Yukihiro ^a   Takeda, Yasutaka ^a   Honjo, Jun ^a   Sakagami, Hidemitsu ^a   Kitsunai, Hiroya ^a   Takiyama, Yumi ^a   Abiko, Atsuko ^a   Makino, Yuichi ^a   Kieffer, Timothy J ^b   Haneda, Masakazu ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Dipeptidyl peptidase 4; Glucagon like peptide 1; Glucose dependent insulinotropic polypeptide; Receptor mediated incretin bioassays

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; LINAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN; DIPEPTIDYL PEPTIDASE IV; DPP4 PROTEIN, HUMAN; GLUCAGON; ISOPROTEIN; PEPTIDE FRAGMENT;

ADULT; ARTICLE; BINDING AFFINITY; BIOASSAY; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HORMONE BINDING; HORMONE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; MALE; ORAL GLUCOSE TOLERANCE TEST; PROTEIN EXPRESSION; BLOOD; GLUCOSE TOLERANCE TEST; METABOLISM; SENSITIVITY AND SPECIFICITY;

ADULT; BLOOD GLUCOSE; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; MALE; PEPTIDE FRAGMENTS; PROTEIN ISOFORMS; SENSITIVITY AND SPECIFICITY;

EID: 85008466082     PISSN: None     EISSN: 22128778     Source Type: Journal    
DOI: 10.1016/j.molmet.2016.12.009     Document Type: Article

References (31)

1. [1] Cho, Y.M., Merchant, C.E., Kieffer, T.J., Targeting the glucagon receptor family for diabetes and obesity therapy. Pharmacology & Therapeutics 135 (2012), 247–278.
2. [2] Fujita, Y., Wideman, R.D., Asadi, A., Yang, G.K., Baker, R., Webber, T., et al. Glucose-dependent insulinotropic polypeptide is expressed in pancreatic islet α-cells and promotes insulin secretion. Gastroenterology 138 (2010), 1966–1975.
3. [3] Fujita, Y., Asadi, A., Yang, G.K., Kwok, Y.N., Kieffer, T.J., Differential processing of pro-glucose-dependent insulinotropic polypeptide in gut. The American Journal of Physiology Gastrointestinal and Liver Physiology 298 (2010), G608–G614.
4. [4] Seino, Y., Kuwata, H., Yabe, D., Incretin-based drugs for type 2 diabetes: focus on East Asian perspectives. Journal of Diabetes Investigation 7:Suppl 1 (2016), 102–109.
5. [5] Yanagimachi, T., Fujita, Y., Takeda, Y., Honjo, J., Atageldiyeva, K.K., Takiyama, Y., et al. Pancreatic glucose-dependent insulinotropic polypeptide (GIP) (1-30) expression is upregulated in diabetes and PEGylated GIP(1-30) can suppress the progression of low-dose-STZ-induced hyperglycaemia in mice. Diabetologia 59 (2016), 533–541.
6. [6] Kieffer, T.J., Heller, R.S., Unson, C.G., Weir, G.C., Habener, J.F., Distribution of glucagon receptors on hormone-specific endocrine cells of rat pancreatic islets. Endocrinology 137 (1996), 5119–5125.
7. [7] Wewer Albrechtsen, N.J., Hartmann, B., Veedfald, S., Windeløv, J.A., Plamboeck, A., Bojsen-Møller, K.N., et al. Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?. Diabetologia 57 (2014), 1919–1926.
8. [8] Bak, M.J., Albrechtsen, N.W., Pedersen, J., Hartmann, B., Christensen, M., Vilsbøll, T., et al. Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans. European Journal of Endocrinology 170 (2014), 529–538.
9. [9] Matsuo, T., Miyagawa, J., Kusunoki, Y., Miuchi, M., Ikawa, T., Akagami, T., et al. Postabsorptive hyperglucagonemia in patients with type 2 diabetes mellitus analyzed with a novel enzyme-linked immunosorbent assay. Journal of Diabetes Investigation 7 (2015), 324–331.
10. [10] Bak, M.J., Wewer Albrechtsen, N.J., Pedersen, J., Knop, F.K., Vilsbøll, T., Jørgensen, N.B., et al. Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): implications for GLP-1 measurements in clinical studies. Diabetes. Obesity and Metabolism 11 (2014), 1155–1164.
11. [11] Mulvihill, E.E., Drucker, D.J., Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocrine Reviews 35 (2014), 992–1019.
12. [12] Omar, B.A., Liehua, L., Yamada, Y., Seino, Y., Marchetti, P., Ahrén, B., Dipeptidyl peptidase 4 (DPP-4) is expressed in mouse and human islets and its activity is decreased in human islets from individuals with type 2 diabetes. Diabetologia 57 (2014), 1876–1883.
13. [13] Mulvihill, E.E., Varin, E.M., Gladanac, B., Campbell, J.E., Ussher, J.R., Baggio, L.L., et al. Cellular sites and mechanisms linking reduction of dipeptidyl peptidase-4 activity to control of incretin hormone action and glucose homeostasis. Cell Metabolism, 2016, 10.1016/j.cmet.2016.10.007 S1550–4131(16) 30538-1. Epub Nov 4.
14. [14] Kieffer, T.J., McIntosh, C.H., Pederson, R.A., Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136 (1995), 3585–3596.
15. [15] Nauck, M.A., Kind, J., Köthe, L.D., Holst, J.J., Deacon, C.F., Broschag, M., et al. Quantification of the contribution of GLP-1 to mediating insulinotropic effects of DPP-4 inhibition with vildagliptin in healthy subjects and patients with type 2 diabetes using exendin [9-39] as a GLP-1 receptor antagonist. Diabetes 65 (2016), 2440–2447.
16. [16] Brubaker, P.L., Efendic, S., Greenberg, G.R., Truncated and full-length glucagon-like peptide-1 (GLP-1) differentially stimulate intestinal somatostatin release. Endocrine 1 (1997), 91–95.
17. [17] Hansen, L., Hartmann, B., Bisgaard, T., Mineo, H., Jørgensen, P.N., Holst, J.J., Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum. American Journal of Physiology Endocrinology and Metabolism 278 (2000), E1010–E1018.
18. [18] Chia, C.W., Carlson, O.D., Kim, W., Shin, Y.K., Charles, C.P., Kim, H.S., et al. Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes. Diabetes 58 (2009), 1342–1349.
19. [19] Christensen, M., Vedtofte, L., Holst, J.J., Vilsbøll, T., Knop, F.K., Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes 60 (2011), 3103–3109.
20. [20] Pospisilik, J.A., Hinke, S.A., Pederson, R.A., Hoffmann, T., Rosche, F., Schlenzig, D., et al. Metabolism of glucagon by dipeptidyl peptidase IV (CD26). Regulatory Peptides 93 (2001), 133–141.
21. [21] Nauck, M.A., Heimesaat, M.M., Orskov, C., Holst, J.J., Ebert, R., Creutzfeldt, W., Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. The Journal of Clinical Investigation 91 (1993), 301–307.
22. [22] Elahi, D., McAloon-Dyke, M., Fukagawa, N.K., Meneilly, G.S., Sclater, A.L., Minaker, K.L., et al. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regulatory Peptides 51 (1994), 63–74.
23. [23] Vilsbøll, T., Krarup, T., Madsbad, S., Holst, J.J., Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 45 (2002), 1111–1119.
24. [24] Nauck, M.A., Kahle, M., Baranov, O., Deacon, C.F., Holst, J.J., Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: a randomized controlled trial in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2016, 10.1111/dom.12802 Epub Oct 6.
25. [25] Aulinger, B.A., Bedorf, A., Kutscherauer, G., de Heer, J., Holst, J.J., Göke, B., et al. Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade. Diabetes 63 (2014), 1079–1092.
26. [26] Hansotia, T., Baggio, L.L., Delmeire, D., Hinke, S.A., Yamada, Y., Tsukiyama, K., et al. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 53 (2004), 1326–1335.
27. [27] Flock, G., Baggio, L.L., Longuet, C., Drucker, D.J., Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes 56 (2007), 3006–3013.
28. [28] Finan, B., Ma, T., Ottaway, N., Müller, T.D., Habegger, K.M., Heppner, K.M., et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Science Translational Medicine, 5, 2013, 209ra151.
29. [29] Widenmaier, S.B., Kim, S.J., Yang, G.K., De Los Reyes, T., Nian, C., Asadi, A., et al. A GIP receptor agonist exhibits beta-cell anti-apoptotic actions in rat models of diabetes resulting in improved beta-cell function and glycemic control. PLoS One, 5, 2010, e9590.
30. [30] Calanna, S., Christensen, M., Holst, J.J., Laferrère, B., Gluud, L.L., Vilsbøll, T., et al. Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes: systematic review and meta-analysis of clinical studies. Diabetes Care 36 (2013), 3346–3352.
31. [31] Calanna, S., Christensen, M., Holst, J.J., Laferrère, B., Gluud, L.L., Vilsbøll, T., et al. Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia 56 (2013), 965–972.